Better Therapeutics Archives - Page 2 of 2

Digital therapeutics open up new opportunities in medical design

A wide range of companies are aiming to make waves through digital therapeutic offerings and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar told Medical Design & Outsourcing. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthcare.”

Read: How DeepWell is developing video games as tools for treating me…

Better Therapeutics reaches key milestones for prescription digital therapeutics

Better Therapeutics (Nasdaq:BTTX) announced today that it hit multiple key research milestones as it validates its digital therapeutics.

San Francisco-based Better Therapeutics develops prescription digital therapeutics designed to deliver a novel form of cognitive-behavioral therapy for treating cardiometabolic diseases, potentially improving key measures related to type 2 diabetes, hypertension and more.

Get the full story at our sister site, Drug Delivery Business News.

Better Therapeutics completes enrollment in type 2 diabetes study

Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes.

San Francisco-based Better Therapeutics’ BT-001 prescription digital therapeutic delivers a novel form of cognitive-behavioral therapy to patients with uncontrolled type 2 diabetes.

Get the full story at our sister site, Drug Delivery Business News.

Better Therapeutics closes SPAC merger, debuts on Nasdaq

Better Therapeutics announced today that it completed its merger with Mountain Crest Acquisition Corp and has gone public on the Nasdaq.

San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. Last month, the company confirmed its expectations for the $113 million SPAC merger to go through by the end of October, as it has today.

Get the full story at our sister site, Drug Delivery Business News.

Better Therapeutics expects $113M SPAC merger to go through in October

Better Therapeutics announced today that it expects its merger with Mountain Crest Acquisition Corp to close next month.

San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. At the time of the announcement, the companies expected the merger to be completed some time in the summer of 2021.

Get the full story at our sister site, Drug Delivery Business News.

Better Therapeutics secures $50M debt facility for digital diabetes treatment tech

Better Therapeutics announced today that it secured a loan debt facility worth up to $50 million from Hercules Capital.

The debt facility provides up to $150 million in total financing when combined with the proceeds from going public through a $113 million merger with SPAC Mountain Crest Acquisition Corp II and a PIPE investment.

Get the full story at our sister site, Drug Delivery Business News.

Better Therapeutics initiates real-world study for digital therapeutic for diabetes

Better Therapeutics announced today that it commenced a real-world evidence study to evaluate its treatment for Type 2 diabetes.

Collaborating with Steward Health Care, Better Therapeutics is evaluating BT-001, an investigational, prescription digital therapeutic (PDT) designed to deliver a novel form of cognitive-behavioral therapy to patients with uncontrolled Type 2 diabetes, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

MedTech 100 roundup: Industry roars back

In the blink of an eye, the medtech industry exited its spring slump and neared its all-time best performance levels.

MassDevice‘s MedTech 100 Index offered signs of a rebound last week and has built on that momentum, registering a final tally of 109.39 points on April 9. That represents a 2.9% increase from the 106.26-point mark set a week prior (April 2).

The industry’s rebound has been impressive, given that just over one month prior, the index had dropped to 102.16 points (March 8), having just set its all-time best of 110.96 on Feb. 15. Medtech companies had no seen that degree of a fall since October 2020.

Improvements highlight the secure position the industry has nestled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 18.5% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 76.1% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The overall …

Better Therapeutics to go public via $113M merger with SPAC

Better Therapeutics announced today that, through a $113 million merger with Mountain Crest Acquisition Corp II, it will go public.

Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), will acquire Better Therapeutics in a deal expected to be completed in the summer of this year, with the company continuing to operate as Better Therapeutics while being listed on the Nasdaq under the BTTX ticker, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.